3.5.8. follow-up. testosterone therapy alleviates symptoms signs hypogonadism men specific time-dependent manner. ttrials clearly showed testosterone therapy improved sexual symptoms early three months initiation . similar results derived meta-analyses . hence, first evaluation planned three months treatment. evaluation may scheduled six months twelve months, according patient characteristics, well results biochemical testing (see below). patients high risk developing elevated haematocrit evaluated every three months first year testosterone therapy least every six months thereafter. accordingly, current guidelines suggest haematocrit maintained 45% patients polycythaemia vera avoid thromboembolism risk . similarly, data derived using multi-institutional database including large cohort hypogonadal (total testosterone < 12 nmol/l) men received testosterone therapy subsequently (n=5,887) (n=4,2784) develop polycythaemia (haematocrit > 52%) showed men increased haematocrit higher risk mace venous thromboembolism mostly first year therapy . risk even higher haematocrit threshold 54% considered whilst risk observed 50% threshold applied . table 6 summarises clinical biochemical parameters monitored testosterone therapy. ttrials designed maintain serum testosterone concentration within normal range young men (280â€“873 ng/dl 9.6-30 nmol/l) . approach resulted good benefit/risk ratio. similar approach could considered follow-up. correct timing evaluation testosterone levels varies according type preparation used (table 5). testosterone involved regulation erythropoiesis prostate growth , hence evaluation psa haematocrit mandatory testosterone therapy. however, important recognise risk pca men aged < 40 years low. similarly, mortality risk pca men aged > 70 years considered high enough warrant monitoring general population . therefore, screening pca determination psa dre men aged < 40 > 70 years testosterone therapy discussed patients. baseline and, least, annual glyco-metabolic profile evaluation may reasonable consideration, particularly management functional hypogonadism. testosterone therapy may beneficial hypogonadal men low moderate fracture risk ; therefore, dual energy x-ray absorptiometry (dexa) bone scan may also considered baseline 18-24 months following testosterone therapy, particularly patients severe hypogonadism . digital rectal examination may detect prostate abnormalities present even men normal psa values. hence, dre mandatory men baseline recommended performed least annually testosterone therapy, long significant increase psa velocity. decision stop testosterone therapy perform prostate biopsy due psa increase prostate abnormalities based local pca guidelines. large consensus increase haematocrit > 54% testosterone therapy requires therapy withdrawal phlebotomy avoid potential adverse effects including venous-thromboembolism cvd, especially high-risk individuals. patients lower risk relevant clinical sequelae, situation alternatively managed reducing testosterone dose switching formulation along venesection. positive family history venous-thromboembolism carefully investigated patient counselled testosterone therapy avoid/prevent thrombophilia-hypofibrinolysis . finally, caution exercised men pre-existing cvd higher risk cvd . table 6: clinical biochemical parameters checked testosterone therapy parametersyear 1 treatmentafter year 1 treatmentbaseline3 months6 months12 monthsannually18-24 monthsclinicalsymptomsxxxxxbody mass indexxxxwaist circumferencexxxxdigital rectal examinationxxxblood pressurexxxxbiochemistrypsa (ng/ml)xxx2xxhaematocrit (%)xxx1,2xxtestosteronexxxxlipid glycaemic profilexxxinstrumentaldexaxx 1population polycythaemia vera high risk secondary polycythaemia (e.g., sleep apnea, morbidobesity, heavy smokers, chronic obstructive pulmonary disease); 2prostate cancer survivors.